Return to Listing

4 result(s) for Melanoma

PI Name Protocol # Title
Sancy Leachman IRB00010561 War on Melanoma: Enlisting a cohort of melanoma survivors and their families
Matthew Taylor STUDY00015298 [NCI CIRB] EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
Matthew Taylor STUDY00015661 [NCI CIRB] S1404: A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma
Alison Skalet STUDY00016162 A Phase 1, Open-label, Multicenter Study Evaluating the Safety and Tolerability, Biologic Activity, Pharmacodynamics, and Pharmacokinetics of Single and Repeated Escalating Intravitreal Doses of ICON-1 in Patients with Uveal Melanoma Who are planned to Undergo Enucleation or Brachytherapy
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080